Saturday 17 October 2026
Export IMCC’s income statement to Excel — free account
IM Cannabis Corp.
IMCC Healthcare Drug Manufacturers Specialty & Generic
IM Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue fell 40.3%, EPS fell 385.7%, free cash flow fell 266.8% and total debt fell 64.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.36
0.03
+2.26%
Follow IMCC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.25 | 0.15 | 0.06 | 0.05 | |
P/FCF ratio |
0.00 | 1.72 | 18.46 | 0.00 | |
P/Operating CF |
(3.69) | 1.95 | (16.16) | (1.87) | |
P/B ratio |
2.99 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.24 | 0.12 | 0.07 | 0.04 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.26) | 1.37 | 18.21 | (2.62) | |
EV/FCF |
(3.25) | 1.36 | 20.18 | (2.56) | |
Quick Ratio |
0.35 | 0.42 | 0.30 | 0.29 | |
Current Ratio |
0.82 | 0.67 | 0.55 | 0.56 | |
Net Debt/EBITDA |
0.17 | 0.26 | (0.22) | 0.66 | |
Debt/Assets |
3.78% | 4.91% | 6.05% | 2.68% | |
Debt/Equity |
0.39 | (0.43) | (0.28) | (0.12) | |
Asset Turnover |
1.15 | 1.53 | 1.52 | 1.39 | |
Operating CF/Net income |
0.95 | (0.56) | 0.08 | 0.26 | |
Capex/Depreciation |
(0.01) | (0.01) | (0.01) | 0.00 | |
Interest Coverage |
(6.09) | (7.00) | (2.01) | (0.72) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
27.49% | 25.54% | 35.66% | 47.37% | |
Intangible Assets out of Total Assets |
0.15 | 0.10 | 0.12 | 0.10 | |
Share Based Compensation of Revenue |
0.01% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.65) | (1.53) | (4.56) | (6.51) | |
Graham Number |
0.00 | 155.52 | 171.23 | 151.06 | |
Earnings Yield |
(40.67%) | (140.68%) | (620.49%) | (1,527.43%) | |
Free Cash Flow Yield |
(29.25%) | 57.99% | 5.42% | (31.29%) | |
Revenue per Share |
62.06 | 79.55 | 32.05 | 17.76 | |
Operating CF per Share |
(15.60) | 21.38 | (0.69) | (2.69) | |
Capex per Share |
(0.02) | (0.02) | (0.02) | 0.00 | |
Free Cash Flow per Share |
(15.62) | 21.35 | (0.71) | (2.70) | |
Cash per Share |
10.38 | 16.77 | 4.25 | 4.07 | |
Shareholders Equity per Share |
19.28 | (18.32) | (18.92) | (13.17) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
19.28 | (18.32) | (18.92) | (13.17) | |
Free Cash Flow |
(2.53) | 3.02 | (0.14) | (0.83) | |
Working Capital |
(4.93) | (8.06) | (9.19) | (9.43) | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
(6.07) | (9.02) | (9.99) | (10.12) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.88 | 8.92 | 8.41 | 7.00 | |
Average Payables |
8.67 | 8.39 | 8.57 | 7.46 | |
Average Inventory |
5.22 | 2.70 | 2.62 | 2.35 | |
Average Assets |
32.45 | 25.66 | 24.28 | 23.76 | |
Average Common Equity |
3.10 | (0.15) | (0.76) | (0.56) |
Columns are period end dates